DALLAS--(BUSINESS WIRE)--GordonMD® Global Investments LP announced today it has participated in a $150 million private placement financing for Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS).
Net proceeds will be used primarily to fund clinical development of TSHA-102 in Rett syndrome and to provide support for program activities for TSHA-120 in giant axonal neuropathy (GAN). Rett syndrome is a rare genetic neurodevelopmental disorder caused by mutations in the X-linked MECP2 gene.
TSHA-102 utilizes a novel miRARE platform designed to mediate levels of MECP2 in the CNS on a cell-by-cell basis without risk of overexpression. TSHA-102 has received Orphan Drug and Rare Pediatric Disease designations from the FDA and has been granted Orphan Drug designation from the European Commission.
“Over the last 13 years, gene therapies have been or are being developed for a wide range of rare diseases, said Craig Gordon, M.D., founder, chief executive officer, and chief investment officer of Gordon MD® Global Investments. I am excited to help fund the development of such a therapy for the potential treatment of Rett Syndrome.
GordonMD® Global Investments LP was founded in 2021 by Craig Gordon, MD, a licensed physician with 13 years of buy-side experience managing global biopharmaceutical portfolios. The firm manages a private fund and a public fund, each focused on differentiated investment opportunities in biopharmaceutical companies primarily located in the U.S., Europe and Japan.
THIS PRESS RELEASE IS INTENDED FOR INFORMATIONAL PURPOSES ONLY. THIS IS NOT AN OFFER OR SOLICITATION WITH RESPECT TO THE PURCHASE OR SALE OF ANY FUND OR SECURITY.